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Abstract
Background: Recent data regarding the comparison of implantable cardioverter-defibrillator (ICD) 
therapy and optimal medical treatment in patients with non-ischemic cardiomyopathy has indicated 
no mortality benefit as a result of ICD therapy. Although the recommendations for ICD implantation 
did not change, it is worth noting that these findings significantly affected the daily practice of ICD 
implantation in Europe.
Methods: To assess the effect of ICD implantation in comparison to pharmacotherapy in the non-
-ischemic cardiomyopathy heart failure population through a systematic review and meta-analysis of the 
available carefully designed prospective randomized controlled trials. Only prospective randomized con-
trolled trials comparing ICD implantation in primary prevention vs. optimal pharmacological therapy 
or placebo and reporting mortality results were included in the meta-analysis. The authors have chosen 
to include the following trials: CAT, AMIOVIRT, DEFINITE, and DANISH.
Results: A meta-analysis of pooled hazard ratios (HR) from all trials conducted on a total of 1789 
patients found that ICD therapy decreased all-cause mortality in comparison to optimal pharmacologi-
cal treatment, with a HR of 0.48 (95% confidence interval [CI] 0.67–1.01); p = 0.06. The data from 
the AMIOVIRT, DANISH, and DEFINITE trials, with a total of 1677 participants, showed a signifi-
cant reduction of sudden cardiac deaths as a result of ICD implantation, with a HR of 0.48 (95% CI 
0.31–0.67); p < 0.001. 
Conclusions: In comparison with optimal medical treatment, ICD implantation in patients with heart 
failure improves the long-term prognosis in terms of sudden cardiac death, with a strong tendency to-
wards all-cause mortality reduction. (Cardiol J)
Key words: implantable cardioverter-defibrillator, meta-analysis, non-ischemic  
cardiomyopathy, systematic review
Introduction
The second half of the 1990s marked the 
beginning of the era of implantable devices for 
patients with heart failure (HF). The first credible 
report came from the Multicenter Automatic De-
fibrillator Implantation Trial (MADIT), published 
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in overall mortality associated with the implanta-
tion of a defibrillator in high-risk patients with 
coronary disease and left ventricular dysfunction, 
asymptomatic unstained ventricular tachycardia, 
and inducible sustained ventricular tachycardia. 
Patients randomly assigned to receive the defibril-
lator had a much lower rate of death from primary 
arrhythmia than patients assigned to conventional 
therapy [1]. Since then, large randomized clinical 
trials have established the role of implantable 
cardioverter-defibrillators (ICDs) in primary pre-
vention, which was reflected in the updated Euro-
pean and American guidelines that assign a class I 
recommendation for prophylactic ICD therapy in 
patients with HF and reduced ejection fraction, 
regardless of HF etiology [2–5]. 
Published in 2016, the report from the Defibril-
lator Implantation in Patients with Non-ischemic 
Systolic Heart Failure (DANISH) trial questions 
the benefits an ICD implantation in patients with 
non-ischemic HF etiology (NICM). A comparison 
of ICD therapy with optimal medical treatment 
(OMT) in patients with NICM reported no mortal-
ity benefit as a result of ICD therapy [6]. Although 
the recommendations for ICD implantation did 
not change after the publication of the DANISH 
trial results, it is worth noting that these findings 
significantly affected the daily practice of ICD im-
plantation in Europe. According to the European 
Heart Rhythm Association survey, many European 
medical centers introduced changes in their indica-
tions for ICD therapy after the publication of the 
DANISH trial results. The DANISH study suc-
ceeded in changing physicians’ attitudes regarding 
ICD indications in the NICM population [7]. 
In light of the above, along with recently 
published findings, we aimed to assess the effect 
of ICDs implanted in the primary prevention of 
sudden cardiac death (SCD), in comparison to 
pharmacotherapy, in the NICM heart failure popu-
lation through a systematic review of the results 
of available credible randomized controlled trials 
(RCTs) and a meta-analysis. 
Methods
Our systematic review and meta-analysis 
were based on established methods recommended 
by the Cochrane guidelines, and they remain in 
compliance with the Preferred Reporting Items for 
Systematic Reviews and Meta-analyses (PRISMA) 
statement [8]. 
Data sources and searches 
The authors searched sources published be-
tween February1980 and January 2020, including 
MEDLINE, EMBASE, PUBMED, the Cochrane 
Central Register of Controlled Trials, and www.
clinicaltrials.gov, without language restriction. In 
February 1980, Dr. Levi Watkins implanted the 
first ICD at Johns Hopkins Hospital. All reports re-
garding RCT and their evaluations were published 
after this date. When searching the clinical trials 
registers, we used the following keywords: non-
ischemic cardiomyopathy, implantable cardioverter 
defibrillator, dilated cardiomyopathy.
Study selection 
Only prospective RCTs including a compari-
son of ICD implantation in primary prevention 
vs. optimal pharmacological therapy or placebo 
and reporting mortality results were included in 
the meta-analysis. Non-randomized, single group 
studies were excluded. Previously published meta-
analyses and systematic reviews that correspond 
with our study selection were included in our 
review. The PRISMA flow chart showing the pub-
lication screening process is depicted in Figure 1. 
Data collection, extraction, analyses,  
and quality assessment
We undertook a meta-analysis of the studies 
where it was reasonable to do so, namely if the 
protocol, participants, and the clinical question 
were comparable enough for pooling data.
We extracted the following data and charac-
teristics: 
 — methods: study design, follow-up duration;
 — participants: inclusion and exclusion criteria, 
number of individuals, clinical characteristics 
(e.g. age, gender, left ventricular ejection 
fraction [LVEF], New York Heart Association 
[NYHA] classification, comorbidities); 
 — medical interventions: ICD implantation, 
optimal pharmacological therapy, placebo, 
concomitant medications;
 — outcomes: primary and secondary outcomes.
Hazard ratios (HRs) with 95% confidence 
intervals (CIs) were abstracted for all available 
mortality outcomes. We pooled the log HRs for 
time-to-event data and used the generic inverse 
variance method for statistical computations and 
graphics in Review Manager 5 software. A p value 
of 0.05 was set as significant. The inconsistency 
index (I2) and p values were used to quantify het-
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erogeneity. In our study a fixed effect was used 
during the statistical analyses.
The risk of bias assessment for each study was 
performed according to the latest revised Cochrane 
risk-of-bias tool for randomized trials (RoB 2). All 
types of bias that could affect the results of rand-
omized trials (bias arising from the randomization 
process due to deviations from intended interven-
tions or missing outcome data, bias in the meas-
urement of the outcome or in the selection of the 
reported result) were considered. We graded each 
potential source of bias as low, high, or unclear, 
and provided a quote from the study report, along 
with a justification for our judgement, in the ‘Risk 
of bias’ table (Table 1).
The role of the funding source 
None of the investigators involved in the 
review received any funding. No external organi-
zations or individuals were involved in any aspect 
of the research. 
Results
The authors decided to include the results of 
the following trials in the meta-analysis: Cardiomyo-
pathy Trial (CAT), Amiodarone Versus Implantable 
Cardioverter-Defibrillator trial (AMIOVIRT), Defi-
brillators in Non-Ischemic Cardiomyopathy Treat-
ment Evaluation Trial (DEFINITE), and DANISH 
[6, 9–11]. They are the only identified RCTs in 
which the experimental and control group were 
NICM. The baseline clinical characteristics of the 
study group are presented in Table 2.
The 4 trials recruited a total of 1789 partici-
pants. All studies included adult patients with the 
mean age of the study population ranging from 52 
(CAT) to 64 years (DANISH). The follow-up period 
in 3 studies was similar (from 22 to 26 months), 
while the DANISH trial reported a substantially 
longer follow-up period, namely 56 months. All 
studies reported sex disproportion, with 70–80% of 
study participants being men. The mean LVEF was 
comparable through all trials, varying from 21.4% 
in DEFINITE to 25% in DANISH. AMIOVIRT 
and DEFINITE included patients in class I–III 
NYHA, CAT — in class III–IV, and DANISH — in 
class II–IV. Regarding comorbidities, the CAT 
trial presented only the atrial fibrillation burden 
(15.7%). However, in this trial alone, the entire 
study population underwent an electrophysiologi-
cal examination. Inducible ventricular tachycardia 
was present in 2.9% of the cases and ventricular 
fibrillation — in 9.6%. Pharmacotherapy was 
substantially diverse across the reports. Beta- 
-blocker administration ranged from 3.8% (CAT) 
to 92% (DANISH). Aldosterone antagonist phar-
macotherapy varied from 19% to 59% (AMIOVIRT 
Records identied through
database searching (n = 506)
Additional records identied 









• Not design of interest (not RCT): n = 3
Full-text articles ecluded, with reasons
• Not intervention of interest (secondary
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 mixed etiology): n = 1
• Not population of interest eligibly criteria
 EF < 40): n = 1
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Figure 1. Study flow diagram; EF — ejection fraction; RCT — randomized controlled trials.
www.cardiologyjournal.org 3
Michał Wasiak et al., ICD in non-ischemic cardiomyopathy: A systematic review and meta-analysis
and DANISH, respectively), while in the CAT 
and DEFINITE trials it was not reported at all. 
Angiotensin-converting-enzyme inhibitors were 
widely used in all trials and rated > 80%. 
Primary endpoint
The meta-analysis of pooled hazard ratios in 
all trials, including a total of 1789 patients, showed 
that all-cause mortality in the ICD group decreased 
with borderline significance (167 of 886 patients, 
i.e. 19%) in comparison to optimal pharmacological 
treatment (195 of 895 patients, i.e. 22%), with a HR 
of 0.48 (95% CI 0.67–0.10); p = 0.06; heterogeneity 
p = 0.78; I2 = 0% (Fig. 2). 
Secondary endpoint
Sudden cardiac deaths were not reported 
in the CAT trial. The data from AMIOVIRT, 
DANISH, and DEFINITE, including a total of 1678 
participants, showed a significant reduction of SCDs 
owing to ICD implantation: 28 of 436 patients vs. 
62 of 841 patients (ICD and conventional care, re-
spectively); with a HR of 0.48 (95% CI 0.31–0.67); 
p < 0.001; heterogeneity p = 0.39; I2 = 0% (Fig. 3).
Health-related quality of life 
A total of 561 participants in the analyzed 
RCTs underwent the quality-of-life evaluation 
(AMIOVIRT and DEFINITE). Investigators used 
the following scales: the Quality of Well-Being 
Schedule (n = 1), the Minnesota Living With 
Heart Failure Questionnaire (MLHFQ), the 12-
-Item Short Form Health Survey (SF-12), and 
the State-Trait Anxiety Inventory. No significant 
differences in the quality of life between two 
groups were noted, which suggests that ICD 
therapy has no measurable effect on a patient’s 
quality of life. 
“Quality assessment”. All of the 4 studies 
included in this meta-analysis had low risk of bias 
regards measurement of the outcome. High risk 
of bias was noticed in deviations from intended 
interventions and selection of the reported result 
in the DANISH trial. Five percent of patients in the 
control group received ICD, and 8% of patients in 
the ICD group did not undergo implantation, or had 
the device deactivated or extracted. The selection 
of the reported result also raised concerns. The 
DANISH trial approved the implantation of a CRT 
device in all eligible patients and then randomized 
the study population to the CRT-D or CRT-P arm. 
Results from patients who required resynchroni-
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Discussion
Meta-analysis
The main finding of our meta-analysis indi-
cates a significant reduction in the SCD rate among 
ICD recipients and a strong tendency towards all- 
-cause mortality reduction in comparison to optimal 
pharmacological treatment alone.
Our findings support the current and binding 
European and American recommendations regard-
ing ICD implantation in the NICM population. 
A few meta-analyses have been published 
in this field in recent years. One of the first was 
a publication presented by Desai et al. [12] with 
pooled data from 5 trials including patients with 
a non-ischemic and mixed etiology of HF (AMIO-
VIRT, CAT, DEFINITE, COMPANION [Compari-
son of Medical Therapy, Pacing, and Defibrillation 
in Heart Failure Trial], and SCD-HeFT [Sudden 
Cardiac Death in Heart Failure Trial]). The authors 
presented a statistically significant 31% reduction 
in all-cause mortality within the ICD population 
Table 2. Baseline clinical characteristics.
Trial name and year of publication
CAT 2002 AMIOVIRT 2003 DEFINITE 2004 DANISH 2016
No participants 104 103 458 1116
Age, mean ± SD [year] 52 ± 11 59 ± 11.5 58* 64*
Follow-up, mean ± SD [month] 66 ± 26.4 24 ± 14.4 29 ± 14 67.6 ± NR
Male 83 (80%) 72 (70%) 326 (71%) 809 (72%)
LVEF, mean ± SD [%] 23 ± 9 21 ± 14 24 ± 7 25 ± NR
ACEI/ARB 100 (96.2%) 88 (85%) 443 (96.7%) 1077 (97%)
Beta-blockers 4 (3.8%) 53 (51.5%) 389 (84.9%) 1026 (92%)
MRA NR 19.4 (20%) NR 58 (646%)
Atrial fibrillation 16 (15.7%) NR 112 248
Arterial hypertension NR 64 NR 348
Diabetes mellitus NR 35 105 211
*Calculated as mean of stated medians for treatment and control groups; ACEI — angiotensin-converting enzyme inhibitor; AMIOVIRT — 
Amiodarone Versus Implantable Cardioverter-Defibrillator; ARB — angiotensin-receptor blocker; CAT — Cardiomyopathy Trial; DANISH —  
Danish Study to Assess the Efficacy of ICDs in Patients with Non-ischemic Systolic Heart Failure on Mortality; DEFINITE — Defibrillators  
in Non-Ischemic Cardiomyopathy Treatment Evaluation Trial; LVEF — left ventricular ejection fraction; MRA — mineralocorticoid receptor 
antagonist; NR — not reported
Figure 2. Hazard ratios for all-cause death: implantable cardioverter-defibrillator (ICD) therapy versus conventional 
care; AMIOVIRT — Amiodarone Versus Implantable Cardioverter-Defibrillator: Randomized Trial in Patients with Non-
ischemic Dilated Cardiomyopathy and Asymptomatic Non-sustained Ventricular Tachycardia; CAT — Cardiomyo-
pathy Trial; Cl — confidence interval; DANISH — Danish Study to Assess the Efficacy of ICDs in Patients with Non-
-ischemic Systolic Heart Failure on Mortality; DEFINITE — Defibrillators in Non-Ischemic Cardiomyopathy Treatment 
Evaluation; ICD — implantable cardioverter-defibrillator
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relative to OMT (risk ratio = 0.69; 95% CI 0.55– 
–0.87; p = 0.002) [12]. A similar study published by 
Romero et al. [13] on the basis of the AMIOVIRT, 
CAT, DEFINITE, COMPANION, SCD-HeFT, and 
DANISH trials reported a significant reduction 
in all-cause mortality in the ICD group compared 
with OMT (risk ratio = 0.79, 95% CI 0.68–0.92; 
p = 0.002). 
Al-Khatib et al. [14] analyzed 4 randomized 
clinical trials (CAT, DEFINITE, SCD-HeFT, 
and DANISH), which included 1874 patients with 
NICM. Pooled data from these trials showed 
a significant reduction in all-cause mortality in 
the ICD group (HR = 0.75; 95% CI 0.61–0.93; 
p = 0.008). The authors excluded the AMIOVIRT 
trial, which was not discussed in the publication. 
Although the results of the trials mentioned 
above coincide with our findings, some differ-
ences in methodology should be noted. The authors 
of those reports included the results from the 
COMPANION and SCD-HeFT trials, although the 
study groups in those trials included patients with is-
chemic and non-ischemic heart failure etiology [12].
A detailed review was presented by El Moheb 
et al. [15]. In their meta-analysis of 6 randomized 
trials including a total of 3128 participants, the au-
thors found that the use of ICD vs. OMT alone de-
creased the risk of all-cause mortality (HR = 0.78, 
95% CI 0.66–0.9). An average of 24 patients needed 
to be treated with ICD to prevent one additional 
death from any cause. Patients under the age of 65 
years gained more benefit than individuals older 
than 65 years (HR = 0.51, 95% CI 0.29–0.91). 
Compared to these meta-analyses, our study 
covers all up-to-date RCTs in which the study 
population consisted exclusively of patients with 
NICM. Furthermore, our study consistently fol-
lowed the latest Cochrane guidelines regarding 
a comprehensive risk of bias evaluation. 
The results of the DANISH trial should be as-
sessed by taking into account the fact that modes 
of death vary with age. SCD rates are roughly 
similar among younger and older patients, while 
the rate of non-SCDs is twice as high in the older 
population, as reported by Elming et al. [16]. 
There was a relation between reduced all-cause 
mortality and ICD therapy in the population of 
patients ≤ 70 years of age (HR = 0.70; 95% CI 
0.51–0.96; p = 0.03), while the population of 
patients > 70 years of age did not show this cor-
relation (HR = 1.05; 95% CI 0.68–1.62; p = 0.84). 
For patients ≤ 70 years of age, the SCD rate was 
1.8 (95% CI 1.3–2.5) and the non-sudden death 
rate was 2.7 (95% CI 2.1–3.5), while for patients 
> 70 years of age, the SCD rate was 1.6 (95% CI 
0.8–3.2) and the non-sudden death rate was 5.4 
(95% CI 3.7–7.8, p = 0.01).
Moreover, the substantial risk of bias in the 
DANISH trial results from the fact that the DANISH 
trial approved the implantation of a CRT device in 
all eligible patients and then randomized the study 
population to the CRT-D or CRT-P arm. Considering 
that 65% of older patients received a CRT device, it 
is likely that the ICD therapy impact on survival was 
diluted by the use of the CRT device in both arms, 
which resulted in the lack of statistical power to 
Figure 3. Hazard ratios for sudden death: implantable cardioverter-defibrillator therapy versus conventional care; 
AMIOVIRT — Amiodarone Versus Implantable Cardioverter-Defibrillator: Randomized Trial in Patients with Non-
-ischemic Dilated Cardiomyopathy and Asymptomatic Non-sustained Ventricular Tachycardia; Cl — confidence 
interval; DANISH — Danish Study to Assess the Efficacy of ICDs in Patients with Non-ischemic Systolic Heart Failure 
on Mortality; DEFINITE — Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation; ICD — implantable 
cardioverter-defibrillator
Hazard Ratio
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present a discrepancy in the survival of patients with 
ICDs, who were not eligible to receive a CRT device.
Registries
The presented meta-analysis encompasses 
prospective RCTs in which the study and control 
groups consisted entirely of patients with NICM. It 
is worthwhile mentioning some recently published 
registries that included patients with NICM and 
ICD implantation. Having analyzed the retrospec-
tive, propensity-matched WARCEF trial (Warfarin 
vs. Aspirin in Reduced Cardiac Ejection Fraction), 
with a mean follow-up of 3.5 ± 1.8 years, the au-
thors noted that the presence of an ICD at baseline 
was associated with a lower risk of all-cause death 
among those with ischemic cardiomyopathy (HR = 
= 0.640; 95% CI 0.45–0.91; p = 0.015), but not among 
those with NICM (HR = 0.984; 95% CI 0.64–1.51; 
p = 0.9) [17]. The major weakness of this study was 
its lack of data regarding the group without ICD im-
plantation. The authors did not report why this group 
(subtracted from the WARCEF population) was not 
initially qualified to ICD implantation. No data relating 
to primary and secondary prevention were provided.
The authors of this publication recently pre-
sented the findings of the COMMIT-HF (Contem-
porary Modalities in the Treatment of Heart Fail-
ure) registry. A comparison between ischemic and 
non-ischemic HF etiology among ICD recipients 
was conducted from January 2009 to December 
2013 with a median of 60.5 months. We observed 
a significantly better clinical profile within the 
non-ischemic group, with a lower mortality rate. 
Furthermore, we discovered that ischemic etiol-
ogy is a strong independent predictor of all-cause 
mortality after ICD implantation [18]. 
Limitations of the study
Our review and meta-analysis have several 
limitations. The follow-up of the included trials 
differs substantially, the p value of heterogeneity 
was nonsignificant, and different medical therapies 
were used across the trials. 
Conclusions
In conclusion, based on the currently avail-
able data, ICD implantation as a primary SCD 
prevention measure is well proven by randomized 
controlled trials. Our meta-analysis strongly sup-
ports the legitimacy of ICD implantation among 
patients with NICM.
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